Related Experiment Video

Updated: Jun 29, 2025

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.4K

Regulation of cancer progression by CK2: an emerging therapeutic target

Shakeel Hussain1, Yilei Guo1, Yu Huo1

  • 1School of Life Sciences, Jiangsu University, Zhenjiang, 212013, Jiangsu, People's Republic of China.

Medical Oncology (Northwood, London, England)
|March 25, 2024
PubMed

Insights

Casein kinase II (CK2) is a key enzyme in cancer progression, regulating cell growth and immune escape. Inhibiting CK2 shows promise as a pivotal cancer therapy strategy.

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Casein kinase II (CK2) is an enzyme with broad kinase activity, phosphorylating numerous substrates.
  • CK2 is implicated in regulating key cellular processes including proliferation, migration, and apoptosis.
  • Elevated CK2 expression correlates with poor prognosis in various cancers.

Purpose of the Study:

  • To review the multifaceted role of CK2 in cancer progression.
  • To explore the potential of CK2 inhibition as a therapeutic strategy in oncology.

Main Methods:

  • Literature review of studies on CK2 function in cancer.
  • Analysis of CK2's involvement in signaling pathways (e.g., JAK2/STAT3, PI3K/AKT).
  • Examination of CK2's impact on the tumor microenvironment and immune response.

Main Results:

  • CK2 regulates critical pathways driving tumor growth, invasion, and metastasis.
  • CK2 influences tumor immune escape by modulating immune cell activity.
  • CK2's involvement in angiogenesis and other cancer-related processes was discussed.

Conclusions:

  • CK2 is a significant regulator of cancer progression and immune evasion.
  • Targeting CK2 presents a promising therapeutic avenue for cancer treatment.
Keywords:
ApoptosisCK2ProliferationTherapyTumor immunity

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K